Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SiLVER05: Sirolimus vs mTOR-Inhibitor-Free Immunosuppression in Liver Transplantation for HCC
NCT00355862Phase 3Completed
- Sponsor
- University of Regensburg
- Start
- Jan 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in hepatocellular carcinoma (HCC) (2 arms), sponsored by University of Regensburg. Primary endpoint: Recurrence-Free Survival at 5 years. Started Jan 2006; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00355862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00355862.